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LETTER TO THE EDITOR
Three cases of anaphylaxis 
following injection of a depot corticosteroid 
with evidence of IgE sensitization to macrogols 
rather than the active steroid
Nicolaj Brandt1, Lene H. Garvey2, Ulla Bindslev‑Jensen1, Henrik Fomsgaard Kjaer1, Carsten Bindslev‑Jensen1 
and Charlotte G. Mortz1* 
Abstract 
We present three cases with anaphylaxis after injection of a depot corticosteroid. First, the steroid was suspected as 
the elicitor, but after evaluation the excipient macrogol was found to be the elicitor. One of the patients had reactions 
to several unrelated drugs. Increased awareness of anaphylaxis to excipients such as macrogols is needed, especially 
when allergy tests for the active drug is negative and in patients with a history of repeated anaphylaxis to seemingly 
unrelated drugs. To establish the correct diagnosis it is important to test with the exact formulation of the culprit drug, 
as well as all the ingredients including excipients.
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To the editor
Macrogols or polyethylene glycols (PEG) are polymers 
used as excipients in many different drugs including depot 
corticosteroid solutions for injection. We present 3 cases 
of anaphylaxis due to macrogol 3350 after injection of a 
depot corticosteroid for arthritis or tendinitis. Evaluation, 
including challenges, with the pure corticosteroid and 
lidocaine was negative. SPT and specific IgE for latex and 
chlorhexidine were negative. In all cases skin prick tests 
(SPT) showed sensitization to macrogol of varying molec-
ular weights, while histamine release (HR) tests to mac-
rogols were negative. Laxatives are the only products on 
the Danish market declaring the concentration of macro-
gol 3350. All three patients underwent open titrated oral 
challenge with the laxative Movicol JuniorR containing 
macrogol 3350 as the active component. Two of the three 
patients reacted with anaphylaxis. The third patient was 
only sensitized by SPT to macrogol 6000, and a challenge 
with a larger dose of macrogol 3350 is planned.
Case 1
A 46 year-old woman developed plantar pruritus, gener-
alized urticaria, nausea and respiratory symptoms 30 min 
after injection with Depo-MedrolR (80 mg) and LidocainR 
due to Achilles tendinitis. The symptoms progressed with 
sensation of throat tightness, dysphagia and hypotension 
and she was treated with intramuscular epinephrine.
One month later, allergy testing was performed: SPT 
with Depo-MedrolR (containing macrogol 3350) was 
positive, while SPT with Solu-MedrolR (containing the 
same steroid component but no macrogol) was nega-
tive. Positive SPT to macrogol 6000 and Movicol JuniorR 
(containing macrogol 3350) were found by titrated SPT 
(Table 1). HR test for both the corticosteroids and mac-
rogols were negative. Titrated intravenous challenge with 
Solu-MedrolR was negative. Five months after the ana-
phylactic reaction an open titrated oral challenge with 
Movicol JuniorR was positive with objective signs after 
the last dose (cumulative dose of 6.56 g macrogol 3350) 
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including itching in the palms, rhinitis and conjunctivi-
tis. Just before the challenge the SPT was repeated with 
Depo-MedrolR and Movicol JuniorR. The SPT was still 
positive for Movicol JuniorR but had become negative to 
Depo-MedrolR, and 1  year after the initial anaphylactic 
reaction both had become negative.
Case 2
A 57  year-old man was admitted to the Emergency 
Department with anaphylactic shock requiring treatment 
with epinephrine after an intraarticular injection with 
80 mg Depo-MedrolR in the knee. Eight years earlier, he 
developed tachycardia, erythema and general discom-
fort after a corticosteroid injection in the shoulder with 
DiprospanR (another steroid drug for injection also con-
taining macrogol 3350) and 4 years earlier he developed 
respiratory symptoms, palpitations and throat tight-
ness with voice change immediately after a colonoscopy, 
where he had received pretreatment with MoviprepR, an 
osmotic laxative containing macrogol 3350.
The patient was referred for evaluation 2  years after 
the reaction to Depo-MedrolR. SPT with Depo-MedrolR, 
DiprophosR and Solu-MedrolR were negative and HR test 
for both the corticosteroids and macrogols were negative 
(Table 1). A titrated challenge with Solu-MedrolR was nega-
tive. SPT was positive for macrogol 20,000 (0.01 and 0.1%) 
and the patient developed generalized urticaria 2 h after the 
SPT. He had an open titrated oral challenge with Movicol 
JuniorR, and developed a systemic reaction after ingestion 
of cumulative 916.5 mg of macrogol 3350. He already had 
subjective symptoms after the first dose, but only developed 
objective symptoms including urticaria and angioedema 
immediately after the fourth dose. Six months later, his 
general practitioner initiated treatment with EscitalopramR, 
containing macrogol 400, and the patient developed urti-
caria a few minutes after ingestion of the first dose.
Case 3
A 63  year-old woman with arthritis developed general 
discomfort, a burning sensation in the soles, erythema 
Table 1 Diagnostic summary of allergy tests
Underline indicates a positive test
Pos positive, neg negative, nt not tested, HR test: Histamin release test
* Contains macrogol 3350, 100% Movicol junior ~104 mg/ml
SPT Tested substance Concentration (%) Case 1 Case 2 Case 3
Corticosteroids Solu‑MedrolR 100 neg neg neg
Depo‑MedrolR* 100 4 mm neg neg
DiprophosR* 100 nt nt neg
Macrogols Macrogol 300 100 neg neg neg
Macrogol 400 100 neg neg neg
Macrogol 3000 100 neg neg neg
Macrogol 6000 100 7 mm neg 5.5 mm
Macrogol 20,000 0.01 neg 5 mm nt
Macrogol 20,000 0.1 neg 9.5 mm nt
Macrogol 20,000 1 neg nt nt
Macrogol 20,000 10 neg nt nt
Laxative Movicol juniorR* 100 5 mm neg neg
Movicol juniorR* 10 3 mm neg nt
Movicol juniorR* 1 neg neg nt
HR test Solu‑MedrolR neg neg nt
Depo‑MedrolR* neg neg neg
DiprophosR* neg neg nt
Macrogol 300 neg neg neg
Macrogol 400 neg neg neg
Macrogol 3000 neg neg neg
Macrogol 6000 neg neg neg
Movicol juniorR* neg neg neg
Challenge Lidocain (subcutaneous) neg nt neg
Movicol juniorR* (peroral) pos pos neg
Solu‑MedrolR (intravenous) neg neg neg
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spreading to the trunk and arms, respiratory symptoms 
and mild hypotension after intraarticular injections 
with 80  mg Depo-MedrolR and LidocainR in the wrist 
and finger joints. She was evaluated a few months later. 
SPT with Depo-MedrolR and Solu-MedrolR were nega-
tive, and intravenous challenge with Solu-MedrolR was 
negative. SPT was positive for macrogol 6000 but nega-
tive for other lower molecular weight macrogols includ-
ing Movicol JuniorR. HR test for both the corticosteroids 
and macrogols were negative. The patient had a titrated 
open challenge with Movicol JuniorR, which was negative 
up to 6.56 g of macrogol 3350. A challenge with a higher 
amount of macrogol 3350 has not been performed due to 
severe co-morbidity.
Discussion
During the last year three patients have been referred to 
our clinic on suspicion of corticosteroid allergy due to 
anaphylactic reactions after depot corticosteroid injec-
tions. All tolerated challenge with the pure corticoster-
oid, but two were found to be oral challenge positive to 
the excipient macrogol 3350 while the third was sensi-
tized in SPT. However, in the third case other elicitors 
were excluded and despite negative challenge with Movi-
col JuniorR up to 6.56 g anaphylaxis to macrogol was still 
suspected. As the clinical effect of osmotic laxatives is 
primarily in the gut and <2% is absorbed [1], the chal-
lenge dose was probably too low in this patient. Due to 
comorbidity we have not yet performed challenge with 
a higher dose of macrogol to verify the allergy. Only 
few case reports of anaphylaxis to macrogols in corti-
costeroid solutions can be found in the literature [2–5]. 
Macrogols are used in many drugs and other products 
including electrolyte lavage solutions, tablets and topical 
products, and anaphylaxis have been described to many 
different formulations via many different administra-
tion routes [6]. In patients with severe allergic reactions 
to chemically unrelated drugs, it is important to con-
sider excipients such as macrogols as potential culprits. 
Unfortunately, this is rarely considered, and patients may 
have several severe reactions before macrogols (or other 
excipients) are suspected as in case 2. When anaphy-
laxis to the active drug is excluded in patients with reac-
tions to unrelated drugs, there is a risk of labelling these 
cases “idiopathic anaphylaxis”, if the excipients in the 
drugs administered are not considered. In such cases the 
patient is at risk of future anaphylaxis on re-exposure to 
the excipients.
The sensitivity and specificity of skin tests and HR 
test evaluated in relation to the outcome of oral chal-
lenge to macrogol are unknown. As systemic reactions 
to skin testing with macrogols have been reported 
in several cases [6], it is important to titrate the skin 
test especially when including the high molecular 
weight macrogols, and furthermore, to extend observa-
tion time to 30  min as development of the wheal may 
be delayed [6]. Case 2 reacted to only high molecular 
weight macrogol in SPT, but was challenge positive to 
macrogol 3350. This finding supports the hypothesis, 
that clinical reactivity to macrogols is related to both 
amount and molecular weight, and although sensitiza-
tion may occur to lower molecular weight macrogols, 
which more readily penetrate skin and mucosa, high 
molecular weight macrogols may subsequently elicit a 
response at lower concentrations [6]. This has implica-
tions for the skin test concentrations used, and it may 
be that SPT with higher molecular weight macrogols 
can be used to diagnose cases with reactions to lower 
molecular weight macrogols in the more distant past, 
as seemed to be the case in case 2. Another important 
finding from these cases is that skin reactivity may 
decrease or even be lost over time as has been shown 
regarding specific IgE for other allergens such as peni-
cillin and chlorhexidine [7, 8]. Case 1 was skin tested 
3 times during the first year, first the SPT was positive 
and then SPT reactivity diminished over time although 
challenge remained positive. Case 2 was not evaluated 
until 2  years after the last anaphylactic episode, and 
SPTs besides macrogol 20,000 were negative at this 
time, but challenge with macrogol 3350 (Movicol Jun-
iorR) was positive. HR test was negative in all cases, and 
was not helpful to predict a reaction to macrogol in our 
cases. The same has been shown in other studies for 
both HR test and basophil activation test in relation to 
macrogol allergy [6].
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